ATE488245T1 - Fusionsproteine - Google Patents

Fusionsproteine

Info

Publication number
ATE488245T1
ATE488245T1 AT05810103T AT05810103T ATE488245T1 AT E488245 T1 ATE488245 T1 AT E488245T1 AT 05810103 T AT05810103 T AT 05810103T AT 05810103 T AT05810103 T AT 05810103T AT E488245 T1 ATE488245 T1 AT E488245T1
Authority
AT
Austria
Prior art keywords
protease
fragment
sensory afferent
nociceptive sensory
site
Prior art date
Application number
AT05810103T
Other languages
English (en)
Inventor
Keith Foster
John Chaddock
Philip Marks
Patrick Stancombe
Roger K Aoki
Joseph Francis
Lance Steward
Original Assignee
Health Prot Agency
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Prot Agency, Allergan Inc filed Critical Health Prot Agency
Priority claimed from PCT/GB2005/004585 external-priority patent/WO2006059093A2/en
Application granted granted Critical
Publication of ATE488245T1 publication Critical patent/ATE488245T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
AT05810103T 2004-12-01 2005-12-01 Fusionsproteine ATE488245T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0426394A GB0426394D0 (en) 2004-12-01 2004-12-01 Fusion proteins
GB0504964A GB0504964D0 (en) 2004-12-01 2005-03-10 Fusion proteins
PCT/GB2005/004585 WO2006059093A2 (en) 2004-12-01 2005-12-01 Fusion proteins

Publications (1)

Publication Number Publication Date
ATE488245T1 true ATE488245T1 (de) 2010-12-15

Family

ID=34043886

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05810103T ATE488245T1 (de) 2004-12-01 2005-12-01 Fusionsproteine

Country Status (13)

Country Link
US (5) US8067200B2 (de)
EP (4) EP2366399B1 (de)
JP (7) JP5174463B2 (de)
AT (1) ATE488245T1 (de)
CY (2) CY1111324T1 (de)
DE (1) DE602005024857D1 (de)
DK (6) DK1877073T3 (de)
ES (6) ES2356179T3 (de)
GB (3) GB0426394D0 (de)
HU (2) HUE025964T2 (de)
PL (3) PL2366399T3 (de)
PT (5) PT1877073E (de)
SI (2) SI1830872T1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7132259B1 (en) * 1999-08-25 2006-11-07 Allergan, Inc. Activatable recombinant neurotoxins
ES2648046T3 (es) 2002-11-12 2017-12-28 The Brigham And Women's Hospital, Inc. Vacuna de polisacárido para infecciones estafilocócicas
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
WO2006068794A2 (en) * 2004-11-22 2006-06-29 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8399400B2 (en) * 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
US8512984B2 (en) * 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8778634B2 (en) * 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
AR060188A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
AR061669A1 (es) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
CN102356091A (zh) 2008-03-14 2012-02-15 阿勒根公司 基于免疫的血清型a肉毒杆菌毒素活性测定
KR101604515B1 (ko) * 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
ES2614990T3 (es) * 2008-06-12 2017-06-02 Ipsen Bioinnovation Limited Proteínas de fusión para uso en el tratamiento de acromegalia
WO2009150470A2 (en) 2008-06-12 2009-12-17 Syntaxin Limited Suppression of cancers
BRPI0916365A2 (pt) 2008-07-21 2018-05-02 Brigham & Womens Hospital Inc métodos e composições relacionados aos oligossacarídeos de glicosina beta-1,6 sintéticos
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
KR20110106346A (ko) 2008-12-10 2011-09-28 알러간, 인코포레이티드 클로스트리디움 독소 약제학적 조성물
DK3281953T3 (da) 2009-03-13 2020-01-20 Allergan Inc Immun-baserede omdirigerede endopeptidase-aktivitetsassays
US8198229B2 (en) * 2009-05-29 2012-06-12 Allergan, Inc. Methods of treating urogenital-neurological disorders using galanin retargeted endopepidases
MX2012006985A (es) * 2009-12-16 2012-09-12 Allergan Inc Toxinas clostridium modificadas que comprenden un dominio de enlace al sitio de escision de la proteasa integrado.
WO2011091419A2 (en) * 2010-01-25 2011-07-28 New York Universiy Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery
JP5956350B2 (ja) 2010-01-25 2016-07-27 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 単鎖タンパク質をそれらの２鎖形態に細胞内変換する方法
MX369263B (es) 2010-05-20 2019-11-04 Allergan Inc Toxinas de clostridium degradables.
WO2012051447A1 (en) 2010-10-14 2012-04-19 Allergan, Inc. Targeted delivery of targeted exocytosis modulators to the sphenopalatine ganglion for treatment of headache disorders
WO2012112420A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Treatments using psma ligand endopeptidases
US20120244188A1 (en) 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
US20120251573A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Neuroendocrine Disorders
US20120251575A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Involuntary Movement Disorders
US20120251574A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20120258132A1 (en) 2011-03-29 2012-10-11 Allergan, Inc. Vagal Nerve-Based Disorders
US20120251515A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Cosmesis Disorders
US20120251518A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
US20120251519A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Smooth Muscle Disorders
US8697090B2 (en) 2011-05-05 2014-04-15 Allergan, Inc. Method of treating persistent genital arousal disorder with a neurotoxin
GB201108108D0 (en) * 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
US9764009B2 (en) 2011-06-13 2017-09-19 Allergan, Inc. Treatment of psychological trauma
AU2012282873B2 (en) 2011-07-08 2016-03-31 Allergan, Inc. Method for treatment of autonomic nervous system disorders
US8992941B2 (en) 2011-07-08 2015-03-31 Allergan, Inc. Method for treatment of esophageal spasm
JP6092205B2 (ja) 2011-07-14 2017-03-08 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 性的行為に関連した失禁の治療方法
US20130171122A1 (en) 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
US10451621B2 (en) 2011-12-31 2019-10-22 Allergan, Inc. Highly sensitive cell-based assay to detect the presence of active botulinum neurotoxin serotype-A
US20140056870A1 (en) * 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
RU2673910C2 (ru) * 2012-11-21 2018-12-03 Ипсен Байоинновейшн Лимитед Способ производства протеолитически процессированного полипептида
EP2934571B1 (de) 2012-12-18 2018-05-30 Allergan, Inc. Prophylaktische behandlung von herpesrezidiven
US9315549B2 (en) 2013-01-28 2016-04-19 New York University Treatment methods using atoxic neurotoxin derivatives
WO2016094555A1 (en) 2014-12-09 2016-06-16 New York University Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
US10369190B2 (en) 2016-09-13 2019-08-06 Allergan, Inc. Non-protein clostridial toxin compositions
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR102483296B1 (ko) 2017-12-26 2022-12-30 가부시키가이샤 굿맨 지혈 기구
US11965191B2 (en) 2018-01-18 2024-04-23 California Institute Of Technology Programmable protein circuits in living cells
US10899823B2 (en) 2018-01-18 2021-01-26 California Institute Of Technology Programmable protein circuits in living cells
DE102018114028A1 (de) * 2018-06-12 2019-12-12 Bundesrepublik Deutschland (Robert Koch-Institut) Probenpräparation für proteomische Untersuchungen
US11453893B2 (en) 2018-08-30 2022-09-27 California Institute Of Technology RNA-based delivery systems with levels of control
US11542305B2 (en) 2018-08-31 2023-01-03 California Institute Of Technology Synthetic protein circuits detecting signal transducer activity
EP3908653A4 (de) 2019-01-10 2022-11-02 California Institute of Technology Synthetisches system zur abstimmbaren schwellenwertbildung von proteinsignalen
GB201900621D0 (en) * 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
EP4277654A1 (de) 2021-01-18 2023-11-22 Conserv Bioscience Limited Immunogene coronavirus-zusammensetzungen, verfahren und verwendungen davon

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
CA2071969A1 (en) * 1989-12-22 1991-06-23 John R. Murphy Hybrid molecules having translocation region and cell-binding region
US5200722A (en) 1991-11-27 1993-04-06 United Solar Systems Corporation Microwave window assembly
AU3658093A (en) 1992-02-10 1993-09-03 Seragen, Inc. Desensitization to specific allergens
GB9305735D0 (en) 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
EP0706563B1 (de) 1993-06-29 2004-10-06 Chiron Corporation Verkürzter keratinocyten-wachstumsfaktor(kgf)mit erhöhter biologischer aktivität
AU2592395A (en) 1994-05-19 1995-12-18 Monsanto Company Method for purifying somatotropin monomers
GB9411138D0 (en) 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
DK0845034T3 (da) 1995-08-15 2003-06-30 Euroscreen Sa Peptid med pronociceptive egenskaber
US6136564A (en) 1995-11-16 2000-10-24 Roche Diagnostics Gmbh Process for the production of peptides by way of streptavidin fusion proteins
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
WO1999003880A1 (en) 1997-07-15 1999-01-28 Novo Nordisk A/S Nociceptin analogues
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
EP1084146B1 (de) 1998-05-13 2002-11-13 BioteCon Gesellschaft für Biotechnologische Entwicklung und Consulting mbH Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
WO2000004926A2 (en) 1998-07-22 2000-02-03 Osprey Pharmaceuticals Limited Conjugates for treating inflammatory disorders and associated tissue damage
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US20040071736A1 (en) * 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
US8790897B2 (en) 1998-08-25 2014-07-29 Syntaxin Ltd. Treatment of mucus hypersecretion
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US6358697B2 (en) 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
US20090018081A1 (en) 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
US20080032931A1 (en) * 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
US7132259B1 (en) * 1999-08-25 2006-11-07 Allergan, Inc. Activatable recombinant neurotoxins
US20030180289A1 (en) 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
PT1234043E (pt) 1999-12-02 2004-07-30 Health Prot Agency Construcoes para a entrega de agentes terapeuticos a celulas neuronais
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US7138127B1 (en) * 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
MXPA03000014A (es) * 2000-06-28 2004-09-13 Ira Sanders Metodos para utilizar con fines beneficiosos toxina tetanica en animales.
ITMI20022022A1 (it) * 2002-09-24 2004-03-25 Girolamo Calo' Analoghi di nocicettina.
GB0228723D0 (en) * 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
US20040115727A1 (en) 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
GB0305149D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
GB0321344D0 (en) * 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
AU2005279741B2 (en) 2004-09-01 2011-10-06 Allergan, Inc. Degradable clostridial toxins
WO2006068794A2 (en) 2004-11-22 2006-06-29 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US7659092B2 (en) * 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
AU2005311098B2 (en) 2004-12-01 2011-08-11 Allergan, Inc. Non-cytotoxic protein conjugates
US8778634B2 (en) * 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
PL1830872T3 (pl) 2004-12-01 2011-09-30 Sec Dep For Health Białka fuzyjne
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
JP2010500967A (ja) 2006-07-20 2010-01-14 ザ ジェネラル ホスピタル コーポレイション コンビナトリアルターゲティングを通じたプロトキシンの選択的活性化のための方法、組成物、およびキット
US20080023928A1 (en) * 2006-07-25 2008-01-31 Lee Cole Quad roller skate
JP2011514307A (ja) 2007-10-23 2011-05-06 アラーガン、インコーポレイテッド 改変クロストリジウム毒素を用いる慢性神経性炎症の治療方法
JP2011514308A (ja) 2007-10-23 2011-05-06 アラーガン、インコーポレイテッド 改変クロストリジウム毒素を用いる泌尿生殖器神経学的障害の治療方法
WO2010085473A1 (en) * 2009-01-20 2010-07-29 Trustees Of Tufts College Methods for the delivery of toxins or enzymatically active portions thereof
US20100303791A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases
US20100303789A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases
US20100303757A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins

Also Published As

Publication number Publication date
US7658933B2 (en) 2010-02-09
DK2366399T3 (en) 2015-06-29
US8067200B2 (en) 2011-11-29
PT2292249E (pt) 2015-07-13
US20090162341A1 (en) 2009-06-25
US20100247509A1 (en) 2010-09-30
PL2366399T3 (pl) 2015-10-30
DK1830872T3 (da) 2011-03-14
DK2335718T3 (en) 2015-09-14
JP5536017B2 (ja) 2014-07-02
DK2292249T3 (en) 2015-07-06
US8187834B2 (en) 2012-05-29
HUE025964T2 (en) 2016-04-28
EP2335718A1 (de) 2011-06-22
CY1114954T1 (el) 2016-12-14
US9139635B2 (en) 2015-09-22
ES2540111T3 (es) 2015-07-08
CY1111324T1 (el) 2015-08-05
JP2012045003A (ja) 2012-03-08
EP2366399A1 (de) 2011-09-21
ES2387013T3 (es) 2012-09-11
PT2366399E (pt) 2015-09-01
EP2335718B1 (de) 2015-06-17
ES2431119T3 (es) 2013-11-25
JP5739854B2 (ja) 2015-06-24
GB0426394D0 (en) 2005-01-05
PT1877073E (pt) 2013-11-25
HUE027025T2 (en) 2016-08-29
EP2292249B1 (de) 2015-06-03
PL2335718T3 (pl) 2015-11-30
SI1877073T1 (sl) 2013-12-31
DE602005024857D1 (de) 2010-12-30
ES2356179T3 (es) 2011-04-05
US20080187960A1 (en) 2008-08-07
PL2292249T3 (pl) 2015-11-30
EP2204182B1 (de) 2012-05-30
US20110177053A1 (en) 2011-07-21
EP2366399B1 (de) 2015-05-06
PT1830872E (pt) 2011-03-15
JP6027035B2 (ja) 2016-11-16
PT2335718E (pt) 2015-10-13
GB0504964D0 (en) 2005-04-20
SI1830872T1 (sl) 2011-04-29
JP2008521424A (ja) 2008-06-26
US8399401B2 (en) 2013-03-19
JP2014087371A (ja) 2014-05-15
ES2547546T3 (es) 2015-10-07
JP2016147907A (ja) 2016-08-18
EP2292249A1 (de) 2011-03-09
DK2204182T3 (da) 2012-07-23
JP5174464B2 (ja) 2013-04-03
DK1877073T3 (da) 2013-11-04
JP2019131585A (ja) 2019-08-08
GB0504966D0 (en) 2005-04-20
JP5174463B2 (ja) 2013-04-03
JP2013063071A (ja) 2013-04-11
JP2008521423A (ja) 2008-06-26
US20120064059A1 (en) 2012-03-15
EP2204182A1 (de) 2010-07-07
ES2548329T3 (es) 2015-10-15

Similar Documents

Publication Publication Date Title
CY1114954T1 (el) Νεα μη-κυτταροτοξικα συζευγματα πρωτεϊνης
WO2006059093A3 (en) Fusion proteins
DK1874807T3 (da) Fusionsproteiner omfattende en ikke-cytotoksisk protease, en targeting-enhed, et protease-spaltningssted og et translokationsdomæne
WO2007138339A3 (en) Treatment of pain by use of a single chain polypeptide fusion protein
MX369005B (es) Proteinas de fusión y usos de las mismas para tratar, prevenir o aliviar el dolor.
WO2006059105A8 (en) Non-cytotoxic protein conjugates
IL261432B1 (en) Induced binding proteins and methods of use
ATE514709T1 (de) Modifizierte clostridientoxine mit erhöhter targeting-kapazität für endogene clostridientoxin-rezeptorsysteme
SI1863920T1 (sl) Postopek za izboljšano izolacijo rekombinantno proizvedenih proteinov
EP2599870A3 (de) Pflanzen mit verbesserten Ertragseigenschaften und Verfahren zu ihrer Herstellung
AU2008220715A8 (en) Plants having enhanced yield-related traits and a method for making the same
ATE521626T1 (de) Fusionsprotein zur inhibierung von gebärmutterhalskrebs
WO2007138336A3 (en) Treatment of pain by single chain, polypeptide fusion protein
MX2012005508A (es) Plantas que tienen mejores rasgos relacionados con el rendimiento y un metodo para producirlas.
DE602006010990D1 (de) Verfahren zur dipeptidherstellung
AU2011220003A8 (en) Plants having enhanced yield-related traits and a method for making the same
JOP20200285A1 (ar) حمض نووي لعلاج حساسية العث
WO2004053061A3 (en) Methods of therapy and diagnosis using targeting of cells that express lax
JOP20200284A1 (ar) حمض نووي لعلاج حساسية القشريات
WO2008039983A3 (en) Methods and compositions using mutant gp120

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1830872

Country of ref document: EP